Plasma ATN biomarkers across the alzheimer's disease continuum in a Chilean community- and clinic-based cohort - PubMed
7 days ago
- #Alzheimer's disease
- #Latin American cohort
- #Plasma biomarkers
- Study evaluates plasma ATN biomarkers (Aβ42/Aβ40, p-tau217, NfL, GFAP) in a Chilean cohort across Alzheimer's disease (AD) stages.
- Participants included cognitively unimpaired (CU), subjective cognitive complaints (SCC), mild cognitive impairment (MCI), and Alzheimer's disease dementia (ADD).
- Results show progressive Aβ42/Aβ40 decline and p-tau217/GFAP elevation across AD stages, with p-tau217 strongly distinguishing ADD from CU (AUC=0.88).
- p-tau217 and NfL levels inversely correlated with cognitive, memory, and functional performance.
- Machine learning models used plasma biomarkers to classify diagnostic categories, highlighting potential for early detection.
- Findings support plasma biomarker utility in AD but emphasize need for further research in underrepresented populations.